Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex
ChiCTR-OPN-16008236Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of everolimus in kidney angiomyolipoma (AML) and tuberous sclerosis complex (TSC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Best response rate. Planned start Jun 2016; status: not yet recruiting.
02
Drugs
everolimus
03
Conditions
kidney angiomyolipoma (AML)tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on ChiCTR-OPN-16008236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-16008236.